factor (VEGF) and its receptors, platelet derived growth factor, fibroblast growth factor and tyrosine kinases [2] . One of the most widely used approaches is to use monoclonal antibodies to neutralize VEGF. However, there is increasing evidence that anti-VEGF therapy increases the risk of complications such as thromboembolic events, arterial hypertension and delayed wound healing in patients with cancer [3] .
MicroRNAs (miRNAs) are small non-coding RNAs (18-24 nucleotides in length), which regulate gene expression with its partial or full anti-sense mechanism in the transcript 3' untranslated region (3' UTR), which modifies protein synthesis. They are transcribed in the nucleus by RNA polymerase II as primary miRNAs containing stem-loop and processed into pre-miRNAs by Drosha. They are then transported to the cytoplasm by exportin 5 and further processed into mature miRNAs by an RNase III enzyme, Dicer. MiRNA duplexes are incorporated into the RNA induced silencing complex and become single stranded miRNAs, which now can partially or completely bind to the target gene 3' UTR.
Due to significant progress in mapping of miRNA complementary binding sites to their target genes, a number of miRNAs have been recently found to be involved in angiogenesis and angiogenesis-related diseases [4] . For instance, endothelial cell specific Dicer and Drosha knockdown enabled the study of differential expression and regulation of miRNAs in endothelial cells, which led to the discovery of a number of pro-and anti-angiogenic miRNAs such as miR-222 [4] . Mimics of anti-angiogenic miRNAs effectively reduce neovascualrization and mimics of pro-angiogenic miRNAs promote angiogenesis [5] . Strategies targeting pro-angiogenic miRNAs or using antiangiogenic RNAs may potentially lead to a safer treatment of vascular diseases than current approaches, since they may provide a more physiological means of inhibition of angiogenic gene expression [6] .
Although there have been successful preclinical studies using synthetic miRNA mimics and anti-miRNAs in in vivo models, there are still a number of challenges translating miRNAs into the clinic. Efficient delivery of Abstract: Angiogenesis is the pathological process of forming new blood vessels from pre-existing vessels. It is one of the main features of many conditions such as cancer and inflammatory diseases. MicroRNAs (miRNAs) are small non-coding RNAs that regulate post-transcriptional gene expression. Recent studies have suggested that miRNAs play a significant role in angiogenesis. The study from Wang et al reported a novel angiomiR, miRNA-329, and its negative correlation with CD 146 expression in angiogenesis. These in vitro and in vivo studies introduce an appealing new way of treating angiogenesis by targeting CD146.
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Commentary
Angiogenesis refers to the development of new blood vessels from pre-existing vessels. Vascular endothelium, the primary component of vessels, acts as the barrier between the circulation and the extracellular space. Vascular endothelium is quiescent under normal conditions, but reacts to diseases such as cancer, artherosclerosis, inflammatory diseases, diabetic retinopathy and age-related macular degeneration by activation and proliferation [1] .
There have been numerous efforts to develop antiangiogenic treatments. Most of these are designed to target molecules involved in angiogenesis and its related signalling pathways, such as vascular endothelial growth
Rapid Communication
Open Access miRNAs to their target sites is one of the biggest challenges, since miRNAs can be easily degraded by nucleases. Several chemical modifications have been used to overcome this problem, however, these have been associated with potential toxicity, decreased miRNA activity, and off-target effects [7] . Studies of delivery methods, toxicity screening and an understanding of biokenetics between drug and the target tissue are therefore of considerable clinical significance. The recent paper by Wang et al reported that miR-329 is a negative regulator of CD146 expression in angiogenesis [8] . Figure 1 summarises possible roles of miR-329 in angiogenesis through CD146. Together with their previous findings targeting CD146 using siRNA and an anti-CD146 antibody blocking CD146-mediated angiogenesis [9, 10] , the present study provides further useful information on the role of CD146 in angiogenesis and how it may be manipulated using miR-329. Their luciferase assays with mutants at 4 possible binding sites of CD146 3'UTR, and their confirmation in vitro study of miR-329 binding sites at sites 1 and 4 were particularly impressive. Through extensive 'gain-and loss-of function' studies with in vitro and in vivo experiments, they also showed that miR-329 diminished VEGF and TNFα-induced SKF/p38 MAPKs/NF-kB activation as well as the expression of multiple angiogenic genes including VEGF, ICAM-1, IL-8 and MMP-9 ( Figure 1) . Another novel aspect of the study is the application of their findings from the in vitro studies to the in vivo model of oxygen induced retinopathy. They took several different approaches to confirm their hypothesis from the in vitro studies to the in vivo model. This study by Wang et al. provides a novel approach to the therapeutic suppression of angiogenesis using miR-329 by directly target proliferating vascular endothelium through CD146. As mentioned in their manuscript, they are currently investigating a potential use of miR-329 in cancer-related angiogenesis. Further studies using this approach are warranted for other angiogenesis-related diseases. 
